Lisocabtagene Maraleucel (Breyanzi)

CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. This review assesses lisocabtagene maraleucel cell suspension in patient-specific single-dose vials, 60 × 106 to 120 × 106 chimeric antigen receptor-positive viable T-cells (consisting of CD4 and CD8 components at a ratio range from 0.8 to 1.2), for IV infusion. Indication: For the treatment of adult patients with relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic therapy, including diffuse large B-cell lymphoma not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and diffuse large B-cell lymphoma arising from follicular lymphoma.